Skip to content

Depression: all studies

Page 103 of 1,034: studies 1,021 to 1,030 of 10,336, newest first. Back to the depression overview

Research

Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action

Biological Psychiatry March 8, 2025 Jonathan Repple, Maximilian Bayas, Chiara Möser et al. 8 citations

After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, particularly rapid-acting antidepressants (RAADs). Despite these promising developments, there remains a significant gap in research on bipolar depression. While several antipsychotics have been investigated for their efficacy in bipolar depression...

DOI: 10.1016/j.biopsych.2025.02.903 (opens in new tab) Mdd #bipolardisorder manic depression Bipolar affective disorder #ketamine ketamine therapy +5

Feasibility of Modified Mindfulness Training Program for Antenatal Depression and Perceived Stress Among Expectant Mothers with Male Child Preference.

Healthcare March 7, 2025 . Badil, Najma Naz, Dildar Muhammad et al. 2 citations

Background/Objectives: Antenatal depression and perceived stress are prevalent mental health challenges faced by pregnant women, and they are associated with male child preference. This study aimed to assess the feasibility of a modified mindfulness training program for reducing antenatal depression and perceived stress levels among expectant mothers with a male child preference at a public...

DOI: 10.3390/healthcare13060584 (opens in new tab) Full text (opens in new tab) Antenatal depression Expectant mothers Male child preference Perceived stress

Risks of using psilocybin in treatment of treatment-resistant depression

Journal of Education, Health and Sport March 7, 2025 Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek et al.

Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, highlighting the potential impact of psilocybin as a promising therapeutic option. However, to ensure its safe and effective integration into clinical practice, it is essential to establish robust safety parameters for its administration. This paper...

DOI: 10.12775/JEHS.2025.79.58319 (opens in new tab) Full text (opens in new tab) Treatment resistant depression Safety Psychedelic assisted therapy Adverse effects +1

Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.

Journal of the American Academy of Child & Adolescent Psychiatry March 7, 2025 Colette Kosik-Gonzalez, Dong-Jing Fu, Li Nancy Chen et al. 14 citations

To evaluate the efficacy, safety, and tolerability of esketamine nasal spray vs psychoactive placebo (oral midazolam) in rapidly reducing depressive symptoms in adolescents with major depressive disorder at imminent risk for suicide. This double-blind, double-dummy, phase 2b study randomized (1:1:1:2) 147 adolescents (12 to <18 years old) to esketamine (28, 56, or 84 mg) or midazolam twice...

Effect of esketamine on reducing postpartum pain and depression.

World Journal of Clinical Cases March 6, 2025 Brandon P Lucke-Wold, Armin Karamian 9 citations

In this editorial, we comment on a recent article by Chen et al, that addressed the effect of intraoperative injection of esketamine on postoperative analgesia and postoperative rehabilitation after cesarean section. Poor management of post-cesarean pain is associated with decreased maternal care for the baby, longer hospitalization, and higher risk of developing postpartum depression....

DOI: 10.12998/wjcc.v13.i7.100422 (opens in new tab) Full text (opens in new tab) Cesarean-section c-section Esketamine-therapy ketamine treatment Postpartum-depression postnatal depression Baby blues +8

Adverse Effects and Safety of Antidepressants and Psychedelics for Depression in Cancer: A Systematic Review of Randomized Controlled Trials

Psychoactives March 4, 2025 Renan Massanobu Maekawa, Lorena T. L. Guerra, José Carlos Bouso et al.

Depression is common among patients suffering from cancer, but is often challenging to diagnose due to the overlap of symptoms with cancer and its treatments. Additionally, treating depression in cancer patients is challenging because of the confusion between the adverse effects of antidepressants, cancer treatments, and cancer symptoms. This study aims to evaluate the safety and adverse...

A brief virtual reality-based mindfulness intervention can improve olfactory perception while reducing depression and anxiety symptoms in university students

Humanities and Social Sciences Communications March 3, 2025 Jingni Ma, Hao-Ke Li, Chuoyan Liang et al.

With universities increasingly offering mindfulness-based interventions to enhance students’ mental health conditions and alleviate the strain on overwhelmed psychological services, this study aimed to investigate the potential effectiveness of a brief VR-based mindfulness intervention for university students with depression and anxiety symptoms. Employing a quasi-experimental design, the...

Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.

BMJ mental health March 3, 2025 Alice Jane Larsen, Giulia Teobaldi, Rosario Isabel Espinoza Jeraldo et al. 10 citations

Depression in older adults is often undertreated. A 2011 systematic review of treatments for treatment-resistant depression (TRD) in older adults identified one placebo-controlled randomised controlled trial (RCT). We aimed to update this review, synthesising evidence for the effectiveness of treatments for TRD in older people. We systematically searched electronic databases (PubMed, Cochrane,...

Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.

The Journal of Clinical Psychiatry March 3, 2025 Guy M. Goodwin, Ania Nowakowska, Merve Atli et al. 14 citations

Background: The largest randomized study of psilocybin to date demonstrated the efficacy of COMP360 25 mg (Compass Pathways' investigational proprietary pharmaceutical-grade synthesized psilocybin formulation) in participants with treatment-resistant depression (COMP 001), compared with 10 mg and 1 mg doses. Here, we report findings from COMP 004, a 52-week observational follow-up of patients...

Depression and Mindfulness: Reclaiming the Past, Present, and Future

Journal of Humanistic Psychology March 1, 2025 Angelos Sofocleous

This article explores the temporal disturbances experienced in depression and the potential effectiveness of mindfulness-based interventions in addressing these disturbances. Drawing upon a Husserlian framework, this article examines the three temporal phases of experience: retention, primal impression, and protention. These phases constitute the temporal fusion that allows us to perceive an...